The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors

Background: Immune checkpoint inhibitors combined chemotherapy (ICIC) are widely used for various types of lung cancer in the past decade. However, ICIC related adverse events (AEs) are more serious than immune-related adverse events (irAE) or cytotoxic chemotherapy alone.Objective: This prospective...

Full description

Bibliographic Details
Main Authors: Wen Kou, Yan Yan Lin, Fei Su, Yue Xiang, Hui Qiao, Xin’An Wu, Xiao-Ming Hou
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pharmacology
Subjects:
pharmaceutical care
immune checkpoint inhibitors
immune-related adverse events
non-small-cell lung cancer
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.910722/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.910722/full

Similar Items